Litfulo (Ritlecitinib Tosylate) Patent Expiration, LOE Window & CMS Spending

Litfulo (Ritlecitinib Tosylate) by Pfizer: FDA Orange Book core substance LOE 2041-10-17, 0 AB generics, $19.1M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN215830 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-10-17
Last Listed Patent or Exclusivity Date2041-10-17
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$19.1M
2024 Medicare Part D Spend$5.1M
2024 Medicaid Spend$14.0M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 16.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.